TipRanks
Atrium Therapeutics, Inc. (RNA)
NASDAQ:RNA
US Market
RNA
Atrium Therapeutics, Inc.
RESEARCH TOOLSreports
Want to see RNA full AI Analyst Report?

Atrium Therapeutics, Inc. (RNA) Income Statement

23 Followers

Atrium Therapeutics, Inc. Income Statement

Last quarter (Q2 2026), Atrium Therapeutics, Inc.'s total revenue was $3.00M, a decrease of -21.91% from the same quarter last year. In Q2, Atrium Therapeutics, Inc.'s net income was $-20.19M. See Atrium Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
$ 18.62M$ 10.90M$ 9.56M$ 9.22M$ 9.33M
Gross Profit
$ 18.62M$ 10.90M$ 7.46M$ 7.84M$ -91.86M
Operating Expenses
$ 95.43M$ 389.83M$ 243.06M$ 186.75M$ 26.20M
Depreciation and Amortization
$ 323.00K$ 2.78M$ 2.10M$ 1.39M$ 639.00K
EBITDA
$ -76.50M$ -376.16M$ -233.50M$ -177.53M$ -117.41M
Operating Income
$ -76.81M$ -378.94M$ -235.60M$ -178.91M$ -118.05M
Other Income/Expenses
$ -12.00K$ 56.63M$ 23.38M$ 4.92M$ 42.00K
Pretax Income
$ -76.83M$ -322.30M$ -212.22M$ -174.00M$ -118.01M
Net Income
$ -76.68M$ -322.30M$ -212.22M$ -174.00M$ -118.01M
Per Share Metrics
Basic EPS
$ -4.48$ -2.89$ -2.91$ -3.34$ -2.85
Diluted EPS
$ -4.48$ -2.89$ -2.91$ -3.34$ -2.85
Weighted Average Shares Outstanding
 17.11M 111.58M 73.01M 52.16M 41.43M
Weighted Average Shares Outstanding (Diluted)
 17.11M 111.58M 73.01M 52.16M 41.43M
Currency in USD

Atrium Therapeutics, Inc. Earnings and Revenue History